| |
AITL
|
ALK unknown ALCL
|
ALK+ ALCL
|
ALK− ALCL
|
ENKL
|
PTCL others
|
PTCL-NOS
|
All
|
|---|
|
Chidamide alone
| | | | | | | | |
|
ORR n (%)
|
32 (49.23)
|
4 (44.44)
|
4 (66.67)
|
3 (37.50)
|
5 (15.15)
|
5 (55.56)
|
47 (37.30)
|
100 (39.06)
|
|
CR n (%)
|
6 (9.23)
|
1 (11.11)
|
4 (66.67)
|
2 (25.00)
|
2 (6.06)
|
1 (11.11)
|
11 (8.73)
|
27 (10.55)
|
|
PR n (%)
|
26 (40.00)
|
3 (33.33)
|
0 (0.00)
|
1 (12.50)
|
3 (9.09)
|
4 (44.44)
|
36 (28.57)
|
73 (28.52)
|
|
DCR n (%)
|
49 (75.38)
|
6 (66.67)
|
5 (83.33)
|
6 (75.00)
|
14 (42.42)
|
6 (66.67)
|
79 (62.70)
|
165 (64.45)
|
|
Chidamide combined with chemotherapy regimens
|
|
ORR n (%)
|
25 (71.43)
|
1 (33.33)
|
2 (100.00)
|
1 (14.29)
|
8 (40.00)
|
3 (75.00)
|
25 (44.64)
|
65 (51. 18)
|
|
CR n (%)
|
4 (11.43)
|
0 (0.00)
|
1 (50.00)
|
0 (0.00)
|
2 (10.00)
|
1 (25.00)
|
7 (12.50)
|
15 (11.81)
|
|
PR n (%)
|
21 (60.00)
|
1 (33.33)
|
1 (50.00)
|
1 (14.29)
|
6 (30.00)
|
2 (50.00)
|
18 (32.14)
|
50 (39.37)
|
|
DCR n (%)
|
31 (88.57)
|
1 (33.33)
|
2 (100.00)
|
5 (71.43)
|
10 (50.00)
|
4 (100.00)
|
41 (73.21)
|
94 (74.02)
|
|
Combined with CHOP-like regimens
|
|
ORR n (%)
|
7 (77.78)
|
1 (50.00)
|
0 (0.00)
|
0 (0.00)
|
1 (33.33)
|
2 (100.00)
|
6 (40.00)
|
17 (53.13)
|
|
CR n (%)
|
2 (22.22)
|
0 (0.00)
|
0 (0.00)
|
0 (0.00)
|
1 (33.33)
|
1 (50.00)
|
0 (0.00)
|
4 (12.50)
|
|
PR n (%)
|
5 (55.56)
|
1 (50.00)
|
0 (0.00)
|
0 (0.00)
|
0 (0.00)
|
1 (50.00)
|
6 (40.00)
|
13 (40.63)
|
|
DCR n (%)
|
9 (100.00)
|
1 (50.00)
|
0 (0.00)
|
1 (100.00)
|
2 (66.67)
|
2 (100.00)
|
11 (73.33)
|
26 (81.25)
|
|
Combined with platinum-containing regimens
|
|
ORR n (%)
|
9 (75.00)
|
0 (0.00)
|
1 (100.00)
|
0 (0.00)
|
3 (42.86)
|
0 (0.00)
|
9 (37.50)
|
22 (45.83)
|
|
CR n (%)
|
0 (0.00)
|
0 (0.00)
|
0 (0.00)
|
0 (0.00)
|
0 (0.00)
|
0 (0.00)
|
4 (16.67)
|
4 (8.33)
|
|
PR n (%)
|
9 (75.00)
|
0 (0.00)
|
1 (100.00)
|
0 (0.00)
|
3 (42.86)
|
0 (0.00)
|
5 (20.83)
|
18 (37.50)
|
|
DCR n (%)
|
11 (91.67)
|
0 (0.00)
|
1 (100.00)
|
2 (66.67)
|
3 (42.86)
|
0 (0.00)
|
15 (62.50)
|
32 (66.67)
|
|
Combined with other regimens
|
|
ORR n (%)
|
9 (64.29)
|
0 (0.00)
|
1 (100.00)
|
1 (33.33)
|
4 (40.00)
|
1 (50.00)
|
10 (58.82)
|
26 (55.32)
|
|
CR n (%)
|
2 (14.29)
|
0 (0.00)
|
1 (100.00)
|
0 (0.00)
|
1 (10.00)
|
0 (0.00)
|
3 (17.65)
|
7 (14.89)
|
|
PR n (%)
|
7 (50.00)
|
0 (0.00)
|
0 (0.00)
|
1 (33.33)
|
3 (30.00)
|
1 (50.00)
|
7 (41.18)
|
19 (40.43)
|
|
DCR n (%)
|
11 (78.57)
|
0 (0.00)
|
1 (100.00)
|
2 (66.67)
|
5 (50.00)
|
2 (100.00)
|
15 (88.24)
|
36 (76.60)
|
-
PTCL-NOS peripheral T cell lymphoma-not otherwise specified, AITL angioimmunoblastic T cell lymphoma, ENKL extranodal natural killer/T cell lymphoma, ALCL anaplastic large cell lymphoma, ORR overall response rate, DCR disease control rate
